Expansion opportunities Bausch & Lomb is actively investing in new technologies and acquisitions (eyeGility inserter, Orphia AI, Acquired Precilens), signaling ongoing growth initiatives and potential bundled sales of ophthalmic devices, education platforms, and specialty lenses.

Education and patient engagement Launch of Orphia AI for cataract patient education indicates a demand for digital patient engagement tools and clinician-facing education platforms that can be cross-sold with surgical devices, lens care products, and pharmaceuticals.

Strategic partnerships Strategic financing involvement with Emmecell and acquisition of Precilens suggest a openness to collaborate on R&D, manufacturing partnerships, and co-developed products, presenting opportunities for co-marketing and distribution deals.

Operational scaling Headcount adjustments and facility changes, including near-term hires and a Hastings closure, highlight potential sales opportunities in supply chain optimization, training services, and consulting around manufacturing efficiency and transition support.

Financial strength and footprint Large revenue footprint and global reach across nearly 100 countries create a broad market for cross-sell of comprehensive eye health portfolios, including contact lenses, lens care, pharmaceuticals, and surgical devices, as well as regionalized promotional and training programs.